Difference between revisions of "How I Treat"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(14 intermediate revisions by the same user not shown)
Line 56: Line 56:
 
===[[Chronic myelomonocytic leukemia|Chronic myelomonocytic leukemia (CMML)]]===
 
===[[Chronic myelomonocytic leukemia|Chronic myelomonocytic leukemia (CMML)]]===
 
*'''2017:''' Solary & Itzykson. [https://doi.org/10.1182/blood-2017-04-736421 How I treat chronic myelomonocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/28572287/ PubMed]
 
*'''2017:''' Solary & Itzykson. [https://doi.org/10.1182/blood-2017-04-736421 How I treat chronic myelomonocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/28572287/ PubMed]
 
===[[Essential thrombocythemia|Essential thrombocythemia (ET)]]===
 
*'''2018:''' Odenike. [https://doi.org/10.1182/blood-2018-03-785907 How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms] [https://pubmed.ncbi.nlm.nih.gov/30333119/ PubMed]
 
*'''2016:''' Rumi & Cazzola. [https://doi.org/10.1182/blood-2016-05-643346 How I treat essential thrombocythemia] [https://pubmed.ncbi.nlm.nih.gov/27561316/ PubMed]
 
  
 
===[[Hypereosinophilic syndrome|Hypereosinophilic syndrome (HES)]]===
 
===[[Hypereosinophilic syndrome|Hypereosinophilic syndrome (HES)]]===
Line 72: Line 68:
 
*'''2013:''' Fenaux & Adès. [https://doi.org/10.1182/blood-2013-02-453068 How we treat lower-risk myelodysplastic syndromes]
 
*'''2013:''' Fenaux & Adès. [https://doi.org/10.1182/blood-2013-02-453068 How we treat lower-risk myelodysplastic syndromes]
  
===[[Myelofibrosis|Myelofibrosis (MF)]]===
+
===[[:Category:Myeloproliferative_neoplasms|Myeloproliferative neoplasms (MPNs)]]===
 +
*'''2024:''' Robinson et al. [https://doi.org/10.1182/blood.2023020729 How I treat myeloproliferative neoplasms in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/38145575/ PubMed]
 +
*'''2018:''' Odenike. [https://doi.org/10.1182/blood-2018-03-785907 How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms] [https://pubmed.ncbi.nlm.nih.gov/30333119/ PubMed]
 +
 
 +
====[[Essential thrombocythemia|Essential thrombocythemia (ET)]]====
 +
*'''2016:''' Rumi & Cazzola. [https://doi.org/10.1182/blood-2016-05-643346 How I treat essential thrombocythemia] [https://pubmed.ncbi.nlm.nih.gov/27561316/ PubMed]
 +
 
 +
====[[Myelofibrosis|Myelofibrosis (MF)]]====
 
*'''2023:''' Kröger et al. [https://doi.org/10.1182/blood.2023021218 How I treat transplant-eligible patients with myelofibrosis] [https://pubmed.ncbi.nlm.nih.gov/37647853/ PubMed]
 
*'''2023:''' Kröger et al. [https://doi.org/10.1182/blood.2023021218 How I treat transplant-eligible patients with myelofibrosis] [https://pubmed.ncbi.nlm.nih.gov/37647853/ PubMed]
*'''2018:''' Odenike. [https://doi.org/10.1182/blood-2018-03-785907 How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms] [https://pubmed.ncbi.nlm.nih.gov/30333119/ PubMed]
 
 
*'''2018:''' Pardanani & Tefferi. [https://doi.org/10.1182/blood-2018-02-785923 How I treat myelofibrosis after failure of JAK inhibitors] [https://pubmed.ncbi.nlm.nih.gov/29866811/ PubMed]
 
*'''2018:''' Pardanani & Tefferi. [https://doi.org/10.1182/blood-2018-02-785923 How I treat myelofibrosis after failure of JAK inhibitors] [https://pubmed.ncbi.nlm.nih.gov/29866811/ PubMed]
 
*'''2011:''' Tefferi. [https://doi.org/10.1182/blood-2010-11-315614 How I treat myelofibrosis] [https://pubmed.ncbi.nlm.nih.gov/21200024/ PubMed]
 
*'''2011:''' Tefferi. [https://doi.org/10.1182/blood-2010-11-315614 How I treat myelofibrosis] [https://pubmed.ncbi.nlm.nih.gov/21200024/ PubMed]
  
===[[Polycythemia vera|Polycythemia vera (PV)]]===
+
====[[Polycythemia vera|Polycythemia vera (PV)]]====
 
*'''2019:''' Spivak. [https://doi.org/10.1182/blood.2018834044 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/31151982/ PubMed]
 
*'''2019:''' Spivak. [https://doi.org/10.1182/blood.2018834044 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/31151982/ PubMed]
*'''2018:''' Odenike. [https://doi.org/10.1182/blood-2018-03-785907 How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms] [https://pubmed.ncbi.nlm.nih.gov/30333119/ PubMed]
 
 
*'''2014:''' Vannucchi. [https://doi.org/10.1182/blood-2014-07-551929 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/25278584/ PubMed]
 
*'''2014:''' Vannucchi. [https://doi.org/10.1182/blood-2014-07-551929 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/25278584/ PubMed]
  
Line 182: Line 183:
  
 
===[[Multiple myeloma|Multiple myeloma (MM)]]===
 
===[[Multiple myeloma|Multiple myeloma (MM)]]===
 +
*'''2024:''' Facon et al. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808246/ How I treat multiple myeloma in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/36693134/ PubMed]
 +
**'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed]
 
*'''2023:''' van de Donk. [https://doi.org/10.1200/jco.22.02114 How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells]
 
*'''2023:''' van de Donk. [https://doi.org/10.1200/jco.22.02114 How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells]
 
*'''2022:''' Kastritis et al. [https://doi.org/10.1182/blood.2020008734 How I treat relapsed multiple myeloma]
 
*'''2022:''' Kastritis et al. [https://doi.org/10.1182/blood.2020008734 How I treat relapsed multiple myeloma]
 +
**'''2014:''' Bladé et al. [https://doi.org/10.1182/blood-2014-10-551531 How I treat relapsed myeloma] [https://pubmed.ncbi.nlm.nih.gov/25587037/ PubMed]
 
*'''2022:''' Perrot. [https://doi.org/10.1182/blood.2020008735 How I treat frontline transplantation-eligible multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/34788422/ PubMed]
 
*'''2022:''' Perrot. [https://doi.org/10.1182/blood.2020008735 How I treat frontline transplantation-eligible multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/34788422/ PubMed]
 
*'''2022:''' Vaxman & Gertz. [https://doi.org/10.1182/blood.2021011670 How I approach smoldering multiple myeloma]
 
*'''2022:''' Vaxman & Gertz. [https://doi.org/10.1182/blood.2021011670 How I approach smoldering multiple myeloma]
 
*'''2022:''' Zamagni et al. [https://doi.org/10.1182/blood.2020008733 How I treat high-risk multiple myeloma]
 
*'''2022:''' Zamagni et al. [https://doi.org/10.1182/blood.2020008733 How I treat high-risk multiple myeloma]
 +
**'''2015:''' Lonial et al. [https://doi.org/10.1182/blood-2015-06-653261 How I treat high-risk myeloma] [https://pubmed.ncbi.nlm.nih.gov/26272217/ PubMed]
 
*'''2017:''' Harousseau & Attal. [https://doi.org/10.1182/blood-2017-03-726703 How I treat first relapse of myeloma] [https://pubmed.ncbi.nlm.nih.gov/28679737/ PubMed]
 
*'''2017:''' Harousseau & Attal. [https://doi.org/10.1182/blood-2017-03-726703 How I treat first relapse of myeloma] [https://pubmed.ncbi.nlm.nih.gov/28679737/ PubMed]
 
*'''2017:''' Moreau. [https://doi.org/10.1182/blood-2017-05-743203 How I treat myeloma with new agents] [https://pubmed.ncbi.nlm.nih.gov/28747306/ PubMed]
 
*'''2017:''' Moreau. [https://doi.org/10.1182/blood-2017-05-743203 How I treat myeloma with new agents] [https://pubmed.ncbi.nlm.nih.gov/28747306/ PubMed]
 
*'''2015:''' Larocca & Palumbo. [https://doi.org/10.1182/blood-2015-05-612960 How I treat fragile myeloma patients] [https://pubmed.ncbi.nlm.nih.gov/26324701/ PubMed]
 
*'''2015:''' Larocca & Palumbo. [https://doi.org/10.1182/blood-2015-05-612960 How I treat fragile myeloma patients] [https://pubmed.ncbi.nlm.nih.gov/26324701/ PubMed]
*'''2015:''' Lonial et al. [https://doi.org/10.1182/blood-2015-06-653261 How I treat high-risk myeloma] [https://pubmed.ncbi.nlm.nih.gov/26272217/ PubMed]
 
 
*'''2015:''' Touzeau & Moreau. [https://doi.org/10.1182/blood-2015-07-635383 How I treat extramedullary myeloma] [https://pubmed.ncbi.nlm.nih.gov/26679866/ PubMed]
 
*'''2015:''' Touzeau & Moreau. [https://doi.org/10.1182/blood-2015-07-635383 How I treat extramedullary myeloma] [https://pubmed.ncbi.nlm.nih.gov/26679866/ PubMed]
*'''2014:''' Bladé et al. [https://doi.org/10.1182/blood-2014-10-551531 How I treat relapsed myeloma] [https://pubmed.ncbi.nlm.nih.gov/25587037/ PubMed]
 
 
*'''2014:''' Gertz & Dingli. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4126328/ How we manage autologous stem cell transplantation for patients with multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/24973360/ PubMed]
 
*'''2014:''' Gertz & Dingli. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4126328/ How we manage autologous stem cell transplantation for patients with multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/24973360/ PubMed]
*'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed]
 
 
*'''2009:''' Stewart et al. [https://doi.org/10.1182/blood-2009-07-204651 How I treat multiple myeloma in younger patients] [https://pubmed.ncbi.nlm.nih.gov/19861683/ PubMed]
 
*'''2009:''' Stewart et al. [https://doi.org/10.1182/blood-2009-07-204651 How I treat multiple myeloma in younger patients] [https://pubmed.ncbi.nlm.nih.gov/19861683/ PubMed]
  
Line 224: Line 226:
  
 
===[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APS)]]===
 
===[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APS)]]===
 +
*'''2024:''' Branch & Lim [https://doi.org/10.1182/blood.2023020727 How I diagnose and treat antiphospholipid syndrome in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/38145574/ PubMed]
 
*'''2021:''' Cohen & Isenberg. [https://doi.org/10.1182/blood.2020004942 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome] [https://pubmed.ncbi.nlm.nih.gov/32898856/ PubMed]
 
*'''2021:''' Cohen & Isenberg. [https://doi.org/10.1182/blood.2020004942 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome] [https://pubmed.ncbi.nlm.nih.gov/32898856/ PubMed]
 
*'''2015:''' Ortel et al. [https://doi.org/10.1182/blood-2014-09-551978 How I treat catastrophic thrombotic syndromes] [https://pubmed.ncbi.nlm.nih.gov/26179082/ PubMed]
 
*'''2015:''' Ortel et al. [https://doi.org/10.1182/blood-2014-09-551978 How I treat catastrophic thrombotic syndromes] [https://pubmed.ncbi.nlm.nih.gov/26179082/ PubMed]
Line 244: Line 247:
 
*'''2021:''' Thomas & Scully. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8555418/ How I treat microangiopathic hemolytic anemia in patients with cancer]
 
*'''2021:''' Thomas & Scully. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8555418/ How I treat microangiopathic hemolytic anemia in patients with cancer]
 
===[[Venous thromboembolism|Venous thromboembolism (VTE)]]===
 
===[[Venous thromboembolism|Venous thromboembolism (VTE)]]===
 +
*'''2024:''' Bhat et al. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10862368/ How I treat pediatric venous thromboembolism in the DOAC era] [https://pubmed.ncbi.nlm.nih.gov/37390311/ PubMed]
 +
**'''2017:''' Young. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813720/ How I treat pediatric venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/28774877/ PubMed]
 
*'''2023:''' Akpan & Hunt. [https://doi.org/10.1182/blood.2021014835 How I approach the prevention and treatment of thrombotic complications in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/37339577/ PubMed]
 
*'''2023:''' Akpan & Hunt. [https://doi.org/10.1182/blood.2021014835 How I approach the prevention and treatment of thrombotic complications in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/37339577/ PubMed]
 
*'''2022:''' Schmidt & Lee. [https://doi.org/10.1182/blood.2019003689 How I treat and prevent venous thrombotic complications in patients with lymphoma]
 
*'''2022:''' Schmidt & Lee. [https://doi.org/10.1182/blood.2019003689 How I treat and prevent venous thrombotic complications in patients with lymphoma]
Line 256: Line 261:
 
*'''2018:''' Vedantham & Sista. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5814931/ How I use catheter-directed interventional therapy to treat patients with venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/29295847/ PubMed]
 
*'''2018:''' Vedantham & Sista. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5814931/ How I use catheter-directed interventional therapy to treat patients with venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/29295847/ PubMed]
 
*'''2017:''' Schulman. [https://doi.org/10.1182/blood-2017-03-742304 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy] [https://pubmed.ncbi.nlm.nih.gov/28483766/ PubMed]
 
*'''2017:''' Schulman. [https://doi.org/10.1182/blood-2017-03-742304 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy] [https://pubmed.ncbi.nlm.nih.gov/28483766/ PubMed]
*'''2017:''' Young. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813720/ How I treat pediatric venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/28774877/ PubMed]
 
 
*'''2015:''' Kyrle. [https://doi.org/10.1182/blood-2015-09-671297 How I treat recurrent deep-vein thrombosis] [https://pubmed.ncbi.nlm.nih.gov/26660685/ PubMed]
 
*'''2015:''' Kyrle. [https://doi.org/10.1182/blood-2015-09-671297 How I treat recurrent deep-vein thrombosis] [https://pubmed.ncbi.nlm.nih.gov/26660685/ PubMed]
 
*'''2015:''' O'Connell. [https://doi.org/10.1182/blood-2014-08-551879 How I treat incidental pulmonary embolism] [https://pubmed.ncbi.nlm.nih.gov/25533036/ PubMed]
 
*'''2015:''' O'Connell. [https://doi.org/10.1182/blood-2014-08-551879 How I treat incidental pulmonary embolism] [https://pubmed.ncbi.nlm.nih.gov/25533036/ PubMed]
Line 264: Line 268:
  
 
===[[Inherited coagulopathy|von Willebrand disease (vWD)]]===
 
===[[Inherited coagulopathy|von Willebrand disease (vWD)]]===
 +
*'''2024:''' Poston & Kruse-Jarres [https://doi.org/10.1182/blood.2022018534 How I treat von Willebrand disorders in older adults] [https://pubmed.ncbi.nlm.nih.gov/37672774/ PubMed]
 
*'''2020:''' Biguzzi et al. [https://doi.org/10.1182/blood.2019003702 How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease]
 
*'''2020:''' Biguzzi et al. [https://doi.org/10.1182/blood.2019003702 How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease]
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
Line 276: Line 281:
  
 
===[[Anemia]]===
 
===[[Anemia]]===
 +
*'''2024:''' Oyedeji et al. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808247/ How I treat anemia in older adults] [https://pubmed.ncbi.nlm.nih.gov/36827619/ PubMed]
 
*'''2023:''' Carson & Brittenham. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10485845/ How I treat anemia with red blood cell transfusion and iron] [https://pubmed.ncbi.nlm.nih.gov/36315909/ PubMed]
 
*'''2023:''' Carson & Brittenham. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10485845/ How I treat anemia with red blood cell transfusion and iron] [https://pubmed.ncbi.nlm.nih.gov/36315909/ PubMed]
 
*'''2021:''' Gurnari & Maciejewski. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8057257/ How I manage acquired pure red cell aplasia in adults]
 
*'''2021:''' Gurnari & Maciejewski. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8057257/ How I manage acquired pure red cell aplasia in adults]
Line 298: Line 304:
  
 
===[[Thrombocytopenia and platelet dysfunction]]===
 
===[[Thrombocytopenia and platelet dysfunction]]===
 +
*'''2024:''' Foy et al. [https://doi.org/10.1182/blood.2022017634 How I diagnose and treat thrombocytopenia in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/37956435/ PubMed]
 +
*'''2024:''' Fogerty & Kuter [https://doi.org/10.1182/blood.2023020726 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37992219/ PubMed]
 +
**'''2012:''' Gernsheimer et al. [https://doi.org/10.1182/blood-2012-08-448944 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/23149846/ PubMed]
 
*'''2023:''' Stanworth & Mumford. [https://doi.org/10.1182/blood.2022018017 How I diagnose and treat neonatal thrombocytopenia] [https://pubmed.ncbi.nlm.nih.gov/36787503/ PubMed]
 
*'''2023:''' Stanworth & Mumford. [https://doi.org/10.1182/blood.2022018017 How I diagnose and treat neonatal thrombocytopenia] [https://pubmed.ncbi.nlm.nih.gov/36787503/ PubMed]
 
*'''2022:''' Stanworth & Shah. [https://doi.org/10.1182/blood.2022016558 How I use platelet transfusions] [https://pubmed.ncbi.nlm.nih.gov/35926105/ PubMed]
 
*'''2022:''' Stanworth & Shah. [https://doi.org/10.1182/blood.2022016558 How I use platelet transfusions] [https://pubmed.ncbi.nlm.nih.gov/35926105/ PubMed]
Line 303: Line 312:
 
*'''2021:''' Kyrle & Eichinger. [https://doi.org/10.1182/blood.2020008218 How I manage cyclic thrombocytopenia]
 
*'''2021:''' Kyrle & Eichinger. [https://doi.org/10.1182/blood.2020008218 How I manage cyclic thrombocytopenia]
 
*'''2016:''' Greinacher & Selleng. [https://doi.org/10.1182/blood-2016-09-693655 How I evaluate and treat thrombocytopenia in the intensive care unit patient] [https://pubmed.ncbi.nlm.nih.gov/28034871/ PubMed]
 
*'''2016:''' Greinacher & Selleng. [https://doi.org/10.1182/blood-2016-09-693655 How I evaluate and treat thrombocytopenia in the intensive care unit patient] [https://pubmed.ncbi.nlm.nih.gov/28034871/ PubMed]
*'''2012:''' Gernsheimer et al. [https://doi.org/10.1182/blood-2012-08-448944 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/23149846/ PubMed]
 
  
 
===[[WHIM syndrome]]===
 
===[[WHIM syndrome]]===
Line 315: Line 323:
  
 
===[[Sickle cell anemia|Sickle cell disease]]===
 
===[[Sickle cell anemia|Sickle cell disease]]===
 +
*'''2024:''' James & Strouse [https://doi.org/10.1182/blood.2023020728 How I treat sickle cell disease in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37979134/ PubMed]
 
*'''2019:''' Stenger et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6923666/ How I treat sickle cell disease with hematopoietic cell transplantation]
 
*'''2019:''' Stenger et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6923666/ How I treat sickle cell disease with hematopoietic cell transplantation]
 
*'''2018:''' Pirenne & Yazdanbakhsh. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6014354/ How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions] [https://pubmed.ncbi.nlm.nih.gov/29724898/ PubMed]
 
*'''2018:''' Pirenne & Yazdanbakhsh. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6014354/ How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions] [https://pubmed.ncbi.nlm.nih.gov/29724898/ PubMed]
Line 349: Line 358:
  
 
===Children===
 
===Children===
 +
*'''2024:''' Bhat et al. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10862368/ How I treat pediatric venous thromboembolism in the DOAC era] [https://pubmed.ncbi.nlm.nih.gov/37390311/ PubMed]
 +
**'''2017:''' Young. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813720/ How I treat pediatric venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/28774877/ PubMed]
 
*'''2023:''' Myers et al. [https://doi.org/10.1182/blood.2022016937 How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL] [https://pubmed.ncbi.nlm.nih.gov/36416729/ PubMed]
 
*'''2023:''' Myers et al. [https://doi.org/10.1182/blood.2022016937 How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL] [https://pubmed.ncbi.nlm.nih.gov/36416729/ PubMed]
 
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed]
 
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed]
Line 357: Line 368:
 
*'''2018:''' Gopal & Gross. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 
*'''2018:''' Gopal & Gross. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 
*'''2018:''' Locatelli & Strahm. [https://doi.org/10.1182/blood-2017-09-765214 How I treat myelodysplastic syndromes of childhood] [https://pubmed.ncbi.nlm.nih.gov/29438960/ PubMed]
 
*'''2018:''' Locatelli & Strahm. [https://doi.org/10.1182/blood-2017-09-765214 How I treat myelodysplastic syndromes of childhood] [https://pubmed.ncbi.nlm.nih.gov/29438960/ PubMed]
*'''2017:''' Young. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813720/ How I treat pediatric venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/28774877/ PubMed]
 
 
*'''2012:''' Locatelli et al. [https://doi.org/10.1182/blood-2012-02-265884 How I treat relapsed childhood acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/22896001/ PubMed]
 
*'''2012:''' Locatelli et al. [https://doi.org/10.1182/blood-2012-02-265884 How I treat relapsed childhood acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/22896001/ PubMed]
  
Line 367: Line 377:
 
*'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed]
 
*'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed]
  
===Older adults===
+
===Older adults/Geriatric hematology===
 +
*'''2024:''' Facon et al. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808246/ How I treat multiple myeloma in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/36693134/ PubMed]
 +
**'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed]
 +
*'''2024:''' Foy et al. [https://doi.org/10.1182/blood.2022017634 How I diagnose and treat thrombocytopenia in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/37956435/ PubMed]
 +
*'''2024:''' Oyedeji et al. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808247/ How I treat anemia in older adults] [https://pubmed.ncbi.nlm.nih.gov/36827619/ PubMed]
 +
*'''2024:''' Poston & Kruse-Jarres [https://doi.org/10.1182/blood.2022018534 How I treat von Willebrand disorders in older adults] [https://pubmed.ncbi.nlm.nih.gov/37672774/ PubMed]
 
*'''2023:''' Lugtenburg & Mutsaers [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed]
 
*'''2023:''' Lugtenburg & Mutsaers [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed]
 
*'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism]
 
*'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism]
Line 373: Line 388:
 
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
 
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
 
*'''2013:''' Gökbuget. [https://doi.org/10.1182/blood-2012-07-379016 How I treat older patients with ALL] [https://pubmed.ncbi.nlm.nih.gov/23673859/ PubMed]
 
*'''2013:''' Gökbuget. [https://doi.org/10.1182/blood-2012-07-379016 How I treat older patients with ALL] [https://pubmed.ncbi.nlm.nih.gov/23673859/ PubMed]
*'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed]
 
  
 
==Complications of treatment==
 
==Complications of treatment==
Line 416: Line 430:
 
*'''2017:''' Boonyawat et al. [https://doi.org/10.1182/blood-2017-07-797423 How I treat heavy menstrual bleeding associated with anticoagulants] [https://pubmed.ncbi.nlm.nih.gov/29092828/ PubMed]
 
*'''2017:''' Boonyawat et al. [https://doi.org/10.1182/blood-2017-07-797423 How I treat heavy menstrual bleeding associated with anticoagulants] [https://pubmed.ncbi.nlm.nih.gov/29092828/ PubMed]
 
===Pregnancy===
 
===Pregnancy===
 +
*'''2024:''' Branch & Lim [https://doi.org/10.1182/blood.2023020727 How I diagnose and treat antiphospholipid syndrome in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/38145574/ PubMed]
 +
*'''2024:''' Fogerty & Kuter [https://doi.org/10.1182/blood.2023020726 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37992219/ PubMed]
 +
**'''2012:''' Gernsheimer et al. [https://doi.org/10.1182/blood-2012-08-448944 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/23149846/ PubMed]
 +
*'''2024:''' James & Strouse [https://doi.org/10.1182/blood.2023020728 How I treat sickle cell disease in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37979134/ PubMed]
 +
*'''2024:''' Robinson et al. [https://doi.org/10.1182/blood.2023020729 How I treat myeloproliferative neoplasms in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/38145575/ PubMed]
 
*'''2022:''' Fiore et al. [https://doi.org/10.1182/blood.2021011595 How I manage pregnancy in women with Glanzmann thrombasthenia]
 
*'''2022:''' Fiore et al. [https://doi.org/10.1182/blood.2021011595 How I manage pregnancy in women with Glanzmann thrombasthenia]
 
*'''2020:''' Dunleavy & McLintock. [https://doi.org/10.1182/blood.2019000961 How I treat lymphoma in pregnancy]
 
*'''2020:''' Dunleavy & McLintock. [https://doi.org/10.1182/blood.2019000961 How I treat lymphoma in pregnancy]
Line 423: Line 442:
 
*'''2016:''' Achebe & Gafter-Gvili. [https://doi.org/10.1182/blood-2016-08-672246 How I treat anemia in pregnancy: iron, cobalamin, and folate] [https://pubmed.ncbi.nlm.nih.gov/28034892/ PubMed]
 
*'''2016:''' Achebe & Gafter-Gvili. [https://doi.org/10.1182/blood-2016-08-672246 How I treat anemia in pregnancy: iron, cobalamin, and folate] [https://pubmed.ncbi.nlm.nih.gov/28034892/ PubMed]
 
*'''2013:''' Milojkovic & Apperley. [https://doi.org/10.1182/blood-2013-08-283580 How I treat leukemia during pregnancy] [https://pubmed.ncbi.nlm.nih.gov/24269956/ PubMed]
 
*'''2013:''' Milojkovic & Apperley. [https://doi.org/10.1182/blood-2013-08-283580 How I treat leukemia during pregnancy] [https://pubmed.ncbi.nlm.nih.gov/24269956/ PubMed]
*'''2012:''' Gernsheimer et al. [https://doi.org/10.1182/blood-2012-08-448944 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/23149846/ PubMed]
 
  
 
===Postpartum period===
 
===Postpartum period===
Line 468: Line 486:
  
 
=Miscellaneous=
 
=Miscellaneous=
 +
==Acute respiratory failure==
 +
*'''2024:''' Azoulay et al. [https://doi.org/10.1182/blood.2023021414 How I manage acute respiratory failure in patients with hematological malignancies] [https://pubmed.ncbi.nlm.nih.gov/38232056/ PubMed]
 +
 
==Atrial fibrillation==
 
==Atrial fibrillation==
 
*'''2016:''' Steinberg. [https://doi.org/10.1182/blood-2016-07-693614 How I use anticoagulation in atrial fibrillation] [https://pubmed.ncbi.nlm.nih.gov/27780804/ PubMed]
 
*'''2016:''' Steinberg. [https://doi.org/10.1182/blood-2016-07-693614 How I use anticoagulation in atrial fibrillation] [https://pubmed.ncbi.nlm.nih.gov/27780804/ PubMed]
 +
 
==Cryoglobulinemia==
 
==Cryoglobulinemia==
 
*'''2016:''' Muchtar et al. [https://doi.org/10.1182/blood-2016-09-719773 How I treat cryoglobulinemia] [https://pubmed.ncbi.nlm.nih.gov/27799164/ PubMed]
 
*'''2016:''' Muchtar et al. [https://doi.org/10.1182/blood-2016-09-719773 How I treat cryoglobulinemia] [https://pubmed.ncbi.nlm.nih.gov/27799164/ PubMed]

Revision as of 11:59, 23 May 2024

The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.

In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. The fourth section contains miscellaneous topics that do not easily fit into the above categories. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.

Malignant hematology

Acute leukemias

Mixed-phenotype acute leukemia (MPAL)

Myeloid neoplasms

Acute lymphoblastic leukemia (ALL)

Acute myeloid leukemia (AML)

Acute promyelocytic leukemia (APL)

Chronic myeloid leukemia (CML)

Chronic myelomonocytic leukemia (CMML)

Hypereosinophilic syndrome (HES)

Myelodysplastic syndrome (MDS)

Myeloproliferative neoplasms (MPNs)

Essential thrombocythemia (ET)

Myelofibrosis (MF)

Polycythemia vera (PV)

Systemic mastocytosis

Lymphoid neoplasms

Adult T-cell leukemia-lymphoma (ATLL)

Anaplastic large cell lymphoma

Burkitt lymphoma (BL)

Castleman disease

Chronic lymphocytic leukemia (CLL/SLL)

Classical Hodgkin lymphoma (cHL)

CNS lymphoma

Cutaneous T-cell lymphoma (CTCL)

Diffuse large B-cell lymphoma (DLBCL)

Follicular lymphoma (FL)

High-grade B-cell lymphoma (HGBL)

HIV-associated lymphoma

Large granular lymphocytic leukemia (T-LGL)

Mantle cell lymphoma (MCL)

NK- and T-cell lymphoma (NKTCL)

Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)

Peripheral T-cell lymphoma (PTCL)

Post-transplant lymphoproliferative disorder (PTLD)

Primary mediastinal B-cell lymphoma (PMBCL)

Prolymphocytic leukemia (T-PLL)

Splenic lymphoma

Transformed lymphoma

Waldenström macroglobulinemia (WM)

Plasma cell dyscrasias

Light-chain (AL) amyloidosis

MGUS

Multiple myeloma (MM)

Plasma cell leukemia (PCL)

Smoldering multiple myeloma (SMM)

Histiocytic disorders

Hemophagocytic lymphohistiocytosis (HLH)

Langerhans cell histiocytosis (LCH)

Classical hematology

Hemostasis and thrombosis

Acquired thrombotic thrombocytopenic purpura (aTTP)

Antiphospholipid antibody syndrome (APS)

Arterial thromboembolism (ATE)

Disseminated intravascular coagulation (DIC)

Hemophilia

Heparin-induced thrombocytopenia (HIT)

Thrombotic microangiopathy (TMA)

Venous thromboembolism (VTE)

von Willebrand disease (vWD)

Cytopenias

Acquired pure red cell aplasia

Anemia

Aplastic anemia

Autoimmune cytopenia

Immune thrombocytopenia (ITP)

Neutropenia & leukopenia

Thrombocytopenia and platelet dysfunction

WHIM syndrome

Hemoglobinopathies

Beta thalassemia

Sickle cell disease

Hemolytic disorders

Cold agglutinin disease (CAD)

Atypical hemolytic uremic syndrome (aHUS)

Paroxysmal nocturnal hemoglobinuria (PNH)

Warm autoimmune hemolytic anemia (WAIHA)

Special considerations

Age-based recommendations

The majority of How I Treat articles focus on "standard" adults; below, articles that focus on other age populations are concatenated.

Neonates

Children

Adolescents and young adults (AYA)

Older adults/Geriatric hematology

Complications of treatment

Bleeding

Cardiovascular complications

Immune effector cells toxicity management

Infectious complications

Iron overload

Medication toxicities

Neurologic medications

Genetic risk

Gynecologic considerations

Menstruation

Pregnancy

Postpartum period

Hospitalization

Regional considerations

Surgical considerations

Transplantation

Allogeneic HSCT

Autologous HSCT

Graft versus host disease (GVHD)

Miscellaneous

Acute respiratory failure

Atrial fibrillation

Cryoglobulinemia

Immunodeficiency

Common variable immune deficiency (CVID)

Severe combined immunodeficiency (SCID)

Priapism

Protoporphyria

T-cell chronic active Epstein-Barr virus disease (CAEBV)